Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep627 | Diabetes therapy | ECE2017

Evaluation and descriptive analysis of our type 1 diabetes population and their insulin therapy

Perdigones Cristina Diaz , Garach Araceli Munoz , Vega Maria Molina , Garcia Carmen Hernandez , Fuentes Miguel Damas , Madueno Francisco J. Tinahones

Objectives: To evaluate the different insulin regimens and types of insulin used in our population of type 1 diabetes (DM1) patients in the last revision in our clinic.Method: A descriptive study was carried out in our population of 535 DM1 patients. They had their initial diagnosis between 1967 and 2014.Results: In our population, 47.3% were women and 52.3% were men. The mean age of our patients was 33.8 years (S.D....

ea0056p25 | Adrenal cortex (to include Cushing's) | ECE2018

Presence of comorbidities related to hypercortisolism in a case series on adrenal incidentaloma (AI)

Cesar Maria Jose Picon , Vega Maria Molina , Garcia Carmen Hernandez , Perdigones Cristina Diaz , Fuentes Miguel Damas , Madueno Francisco Tinahones

Introduction: The European Society of Endocrinology Clinical Practice Guideline defines follow-up recommendations for AI based on the 1 mg overnight dexamethasone suppression test and the presence of associated comorbidities. Follow-up is not recommended for AI presenting serum cortisol levels post dexamethasone ≤1.8 μg/dl neither those presenting serum cortisol levels post dexamethasone between 1.9–5 μg/dl (defined as ‘possible autonomous cortisol se...

ea0073aep213 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Analysis of lipid profile in a sample of patients with type 1 diabetes (T1D)

Fuentes-Damas Miguel , Garcia Carmen Hernandez , Jose Ignacio Martinez Montoro , Valero Andrea Fernandez , Francisco Tinahones Madueño

IntroductionDyslipidemia is a major cardiovascular risk factor, being its detection and control essential due to risk of serious complications. Numerous trials have demonstrated its relationship with T2D, but it has not been so well studied in T1D.ObjectiveTo obtain information about relationship between dyslipidemia and T1D and analyze its prevalence and control in a sample of patients.<p class="abstext"...

ea0056p299 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2018

PCSK9 inhibitors as an add on for the treatment of dislipemia in real clinical practice

Garcia Carmen Hernandez , Perdigones Cristina Maria Diaz , Fuentes Miguel Damas , Martinez Clara Estaun , Ramos Andrea Sanchez , Ramos Ana Molina , Madueno Francisco Tinahones

Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...

ea0056p490 | Diabetes therapy | ECE2018

Experience in clinical practice with new long-acting insulins in type 2 diabetes (T2D)

Vega Maria Molina , Garach Araceli Munoz , Fuentes Miguel Damas , Garcia Carmen Hernandez , Perdigones Cristina Diaz , Pareja Isabel Cornejo , Madueno Francisco Tinahones

Introduction: New long-acting insulin analogues (insulin degludec –ID- and insulin glargine 300 U/ml –IG300-) have proved, in clinical trials, that improve metabolic control with lower hypoglycemia rate in T2D.Objective: To assess characteristics of T2D patients who were given ID and IG300 and to evaluate their effect on metabolic control, weight and insulin dose.Material and methods: We studied T2D patients whose treatme...